Geometric mean titers (GMT) of neutralizing antibody were noninferior among adolescents compared with young adults (GMT ratio: 1.08, 95% CI 0.94-1.24). Most vaccinated persons seroconverted (98.8% of adolescents, 98.6% of young adults).No serious adverse events related to mRNA-1273 or placebo were noted. Most common side effects within 7 days of 1 st and 2 nd dose, respectively, were injection site pain (93.1% and 92.4%), headache (44.6% and 70.2%), and fatigue (47.9% and 67.8%).mRNA-1273 vaccine (100 micrograms per dose) had an acceptable safety profile in adolescents.Several authors are employees of Moderna, which funded the study.Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents external icon. "In this interim analysis of the ongoing trial, the overall benefit-risk profile of mRNA-1273 was favorable in adolescents," the authors write. In the mRNA-1273 vaccine group, there were no reported cases of COVID-19 within 14 days after the second injection compared with four cases in the placebo group. Relative to young adults (age 18 to 25 years), the geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents was 1.08 (95 percent confidence interval, 0.94 to 1.24) and the absolute difference in serologic response was 0.2 percentage points (95 percent confidence interval, −1.8 to 2.4), meeting noninferiority criterion. There were no serious adverse events related to the mRNA-1273 vaccine or placebo reported. The researchers found that the most common solicited adverse reactions after the first and second injections were injection-site pain (93.1 and 92.4 percent, respectively), headache (44.6 and 70.2 percent, respectively), and fatigue (47.9 and 67.8 percent, respectively) in the mRNA-1273 group and injection-site pain (34.8 and 30.3 percent, respectively) headache (38.5 and 30.2 percent, respectively), and fatigue (36.6 and 28.9 percent, respectively) in the placebo group. Kashif Ali, M.D., from Kool Kids Pediatrics in Houston, and colleagues randomly assigned 3,732 healthy adolescents aged 12 to 17 years in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine or placebo (2,489 and 1,243, respectively) 28 days apart, as part of an ongoing phase 2/3 trial. 11 in the New England Journal of Medicine. 12, 2021 (HealthDay News) - The results of an interim analysis suggest that two doses of the Moderna mRNA-1273 vaccine safely induce protective levels of antibodies to SARS-CoV-2 among adolescents, according to a study published online Aug. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report. All of our articles are chosen independent of any financial interests. HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. Any known potential conflicts of interest associated with a study or source are made clear to the reader.Įditorial and Fact-Checking Policy for more detail.Įditorial and Fact-Checking Policy HealthDay Editorial Commitment.Each article includes a link or reference to the original source.Peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations. Unless otherwise noted, all articles focusing on new research are based on studies published in.All articles are edited and checked for factual accuracy by our. ![]() ![]() Team of industry experts to ensure accuracy. ![]() Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a HealthDay operates under the strictest editorial standards.
0 Comments
Leave a Reply. |